JMP Securities lowered the firm’s price target on Rezolute to $7 from $8 and keeps an Outperform rating on the shares. The Phase 3 sunRIZE study of RZ358 on track to initiate in Q4, ahead of DME Phase 2 results in 1Q24, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RZLT:
